Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The COVID-19 Prevention Network (CoVPN) is doing a study to estimate the number of people who have or have had the SARS-CoV-2 virus in different communities in the United States. This study is being done to help determine the best places to perform future research studies that will test new drugs for treatment or prevention of COVID-19.
Design:
Cross-sectional surveys of (1) adults residing in senior living facilities and attending outpatient healthcare facilities, and (2) the general population in each selected research site community.
Population:
Study Size:
For each research site, up to 3,920 individuals will be enrolled from one, two, or all three of the following populations (must include at least community venues):
Total sample size = 3,920 x up to 20 clinical research sites
Study Duration:
Approximately sixteen (16) months for overall project. Two (2) months for protocol development and institutional review board (IRB) approval, followed by:
Facility-based surveys: 12 months (3 months for site preparation and initiation, 3 months for enrollment/sample collection, 4 months for shipping and laboratory testing*, 2 months for close-out), concurrent with
Time-location sampling (TLS) surveys: 14 months (3 months for site preparation and initiation, 6 months for enrollment/sample collection, 6 months for shipping and laboratory testing*, 2 months for close-out)
Study Location:
Catchment areas surrounding US-based Clinical Research Sites (CRSs) of the: HIV Prevention Trials Network (HPTN), HIV Vaccine Trials Network (HVTN), Infectious Diseases Clinical Research Consortium (IDCRC), International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), and the AIDS Clinical Trials Group (ACTG); to be specified in the Site Announcement Memo
Study Methods:
Blood collection for SARS-CoV-2 antibody testing and characterization of the serologic response to SARS-CoV-2 infection; nasal mid-turbinate swab collection for SARS-CoV-2 RNA testing; collection of saliva in a subset of participants to evaluate the performance of diagnostic SARS-CoV-2 assays using these matrices; administration of tablet-based survey. Medical records abstraction for senior living facility participants who are unable to respond to the study survey.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Senior Living Facilities | Adults residing in senior living facilities (nursing homes, assisted or independent living facilities) | ||
| Outpatient Healthcare Facilities | Adults attending outpatient healthcare in neighborhoods of selected research sites | ||
| General Communities | Adults and children (>2 months of age) in neighborhoods of selected research sites |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| To estimate the prevalence of SARS-CoV-2 IgG seropositivity among individuals in communities surrounding selected NIAID clinical research sites | Baseline |
| Measure | Description | Time Frame |
|---|---|---|
| To estimate prevalence of SARS-CoV-2 infection based on results of SARS-CoV-2 RNA testing | Baseline | |
| To estimate prevalence of SARS-CoV-2 infection by presence versus absence of symptoms consistent with COVID-19 | Baseline |
Not provided
Inclusion Criteria:
Adults residing in senior living facilities or attending outpatient healthcare facilities:
Adults and children from select neighborhoods of research site communities:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adults residing in nursing homes or attending outpatient healthcare facilities in neighborhoods of selected research sites. Adults and children (>2 month of age) in neighborhoods of selected research sites.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jessica Justman, MD | Departments of Epidemiology and Medicine, Columbia University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital Colorado CRS | Aurora | Colorado | 80045 | United States | ||
| U of Miami, IDRU at Jackson Memorial Hospital CRS |
Not provided
| Label | URL |
|---|---|
| COVID-19 Nursing Home Data \[Internet\].2020 \[cited 06/08/2020\] | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jul 24, 2025 | |
| Reset | Aug 8, 2025 | |
| Release | Sep 5, 2025 | |
| Reset | Sep 26, 2025 |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_ICF | Yes | No | Yes | Study Protocol and Informed Consent Form | May 26, 2021 | Sep 13, 2021 | Prot_ICF_000.pdf |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jul 24, 2025 | Aug 8, 2025 | |||
| Sep 5, 2025 |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood collection, nasal mid-turbinate swab, and saliva
| To estimate seroprevalence of SARS-CoV-2 | Among:
| Baseline |
| To assess association between demographic, clinical and social factors with SARS-CoV-2 infection and seroprevalence, with particular interest in racial and ethnic health disparities. | Logistic regression using survey weights will be used to infer associations between the hypothesized socioeconomic, demographic and clinical predictors of SARS-CoV-2 infection and seroprevalence. | Baseline |
| To estimate potential size of populations for referral to COVID-19 prevention and treatment studies | Baseline |
| To assess knowledge, attitudes, and behavior about SARS-CoV-2 and COVID-19 through a study questionnaire | Baseline |
| To assess performance characteristics of PCR-based and serologic SARS-CoV-2 tests using saliva samples | Baseline |
| Miami |
| Florida |
| 33136 |
| United States |
| The Ponce de Leon Center CRS | Atlanta | Georgia | 30308 | United States |
| UIC Project Wish CRS | Chicago | Illinois | 60612 | United States |
| New Orleans Adolescent Trials Unit CRS | New Orleans | Louisiana | 70118 | United States |
| John's Hopkins CRS | Baltimore | Maryland | 21218 | United States |
| New Jersey Medical School CRS | Newark | New Jersey | 07103 | United States |
| Harlem Prevention | New York | New York | 10027 | United States |
| Physicians & Surgeons CRS | New York | New York | 10032 | United States |
| Bronx Prevention Center | New York | New York | 10451 | United States |
| Cincinnati CRS | Cincinnati | Ohio | 45229 | United States |
| Penn Prevention CRS | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15260 | United States |
| Baylor College of Medicine | Houston | Texas | 77030 | United States |
| St. Louis University VTEU-CAIMED-PHSU | Ponce | Puerto Rico |
| Sep 26, 2025 |
| Jun 18, 2026 |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |